Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 129

1.

Phase 3 (COSMIC-312) study of cabozantinib in combination with atezolizumab vs sorafenib in patients with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy.

Rimassa L, Cheng A, Braiteh F, Benzaghou F, Hazra S, Borgman A, Sinha R, Kayali Z, Zhu A, Kelley R.

Ann Oncol. 2019 Jul;30 Suppl 4:iv65-iv66. doi: 10.1093/annonc/mdz155.237. Epub 2019 Dec 4. No abstract available.

PMID:
32085245
2.

A randomized, multicenter, phase 2 trial comparing CAPTEM versus FOLFIRI as second-line treatment for MGMT-methylated, RAS-mutated metastatic colorectal cancer patients.

Pietrantonio F, Lobefaro R, Antista M, Miceli R, Raimondi A, Lonardi S, Rimassa L, Saggio S, Capone I, Farina G, Longarini R, Mosconi S, Bianchi AS, Tomasello G, Petrelli F, Murgioni S, Perrone F, Barault L, Milione M, Nicolantonio FD, Bartolomeo MD, de Braud F.

Ann Oncol. 2019 Jul;30 Suppl 4:iv135. doi: 10.1093/annonc/mdz154.024. Epub 2019 Dec 4. No abstract available.

PMID:
32085043
3.

Role of stereotactic body radiation therapy in the management of oligometastatic pancreatic cancer: single institution experience.

Scorsetti M, Comito T, Franzese C, Franceschini D, De Rose F, Tomatis S, D'alessio A, Prete M, Bozzarelli S, Rimassa L, Personeni N, Santoro A.

Ann Oncol. 2019 Jul;30 Suppl 4:iv107. doi: 10.1093/annonc/mdz155.392. Epub 2019 Dec 4. No abstract available.

PMID:
32084958
4.

Medical oncologists must get more involved in systemic treatment.

Raoul JL, Faivre S, Frenel JS, Rimassa L.

Ann Oncol. 2019 Jan;30(1):6-8. doi: 10.1093/annonc/mdy471. Epub 2020 Jan 8. No abstract available.

5.

Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.

Petrelli F, Labianca R, Zaniboni A, Lonardi S, Galli F, Rulli E, Rosati G, Corallo S, Ronzoni M, Cardellino GG, Mattioli R, Mambrini A, Ciuffreda L, Banzi M, Pusceddu V, Maiello E, Zampino M, Zagonel V, Marchetti P, Corsi D, Rimassa L, Cinieri S, Sobrero A.

JAMA Oncol. 2020 Feb 13. doi: 10.1001/jamaoncol.2019.6486. [Epub ahead of print]

PMID:
32053133
6.

Khorana score and thromboembolic risk in stage II-III colorectal cancer patients: a post hoc analysis from the adjuvant TOSCA trial.

Barni S, Rosati G, Lonardi S, Pella N, Banzi M, Zampino MG, Dotti KF, Rimassa L, Marchetti P, Maiello E, Artioli F, Ferrari D, Labianca R, Bidoli P, Zaniboni A, Sobrero A, Iaffaioli V, De Placido S, Frassineti GL, Ciarlo A, Buonadonna A, Silvestris N, Piazza E, Pavesi L, Moroni M, Clerico M, Aglietta M, Giordani P, Galli F, Galli F, Petrelli F.

Ther Adv Med Oncol. 2020 Jan 20;12:1758835919899850. doi: 10.1177/1758835919899850. eCollection 2020.

7.

Molecular therapies for HCC: Looking outside the box.

Faivre S, Rimassa L, Finn RS.

J Hepatol. 2020 Feb;72(2):342-352. doi: 10.1016/j.jhep.2019.09.010. Review.

PMID:
31954496
8.

Predictive Impact of Mucinous Tumors on the Clinical Outcome in Patients with Poorly Differentiated, Stage II Colon Cancer: A TOSCA Subgroup Analysis.

Rosati G, Galli F, Cantore M, Bergamo F, Banzi M, Zampino MG, Mattioli R, Cardellino GG, Ronzoni M, Di Bartolomeo M, Tamberi S, Marchetti P, Rimassa L, Corsi D, Bochicchio AM, Artioli F, Labianca R, Galli F, Rulli E, Bilancia D, Bregni G; TOSCA (Three or Six Colon Adjuvant) Investigators.

Oncologist. 2020 Jan 13. doi: 10.1634/theoncologist.2019-0736. [Epub ahead of print]

9.

Modulation of biliary cancer chemo-resistance through microRNA-mediated rewiring of the expansion of CD133+ cells.

Carotenuto P, Hedayat S, Fassan M, Cardinale V, Lampis A, Guzzardo V, Vicentini C, Scarpa A, Cascione L, Costantini D, Carpino G, Alvaro D, Ghidini M, Trevisani F, Te Poele R, Salati M, Ventura S, Vlachogiannis G, Hahne JC, Boulter L, Forbes SJ, Guest R, Cillo U, Said-Huntingford I, Begum R, Smyth E, Michalarea V, Cunningham D, Rimassa L, Santoro A, Roncalli M, Kirnkin V, Clarke P, Workman P, Valeri N, Braconi C.

Hepatology. 2019 Dec 26. doi: 10.1002/hep.31094. [Epub ahead of print]

PMID:
31879968
10.

Is there an oligometastatic state in pancreatic cancer? Practical clinical considerations raise the question.

Scorsetti M, Comito T, Franceschini D, Franzese C, Prete MG, D'Alessio A, Bozzarelli S, Rimassa L, Santoro A.

Br J Radiol. 2020 Feb 1;93(1106):20190627. doi: 10.1259/bjr.20190627. Epub 2019 Dec 18.

PMID:
31825664
11.

Systemic Treatment Options in Hepatocellular Carcinoma.

Rimassa L, Pressiani T, Merle P.

Liver Cancer. 2019 Nov;8(6):427-446. doi: 10.1159/000499765. Epub 2019 May 29. Review.

12.

Corrigendum to "Gastric cancer: Translating novels concepts into clinical practice" [Cancer Treatm. Rev. 79C (2019) 101889].

Salati M, Orsi G, Smyth E, Aprile G, Beretta G, De Vita F, Di Bartolomeo M, Fanotto V, Lonardi S, Morano F, Pietrantonio F, Pinto C, Rimassa L, Vasile E, Vivaldi C, Zaniboni A, Ziranu P, Cascinu S.

Cancer Treat Rev. 2019 Dec;81:101932. doi: 10.1016/j.ctrv.2019.101932. Epub 2019 Nov 23. No abstract available.

PMID:
31771795
13.

Regorafenib in patients with refractory metastatic pancreatic cancer: a Phase II study (RESOUND).

Bozzarelli S, Rimassa L, Giordano L, Sala S, Tronconi MC, Pressiani T, Smiroldo V, Prete MG, Spaggiari P, Personeni N, Santoro A.

Future Oncol. 2019 Dec;15(35):4009-4017. doi: 10.2217/fon-2019-0480. Epub 2019 Nov 20.

PMID:
31746632
14.

Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer.

Pietrantonio F, Lobefaro R, Antista M, Lonardi S, Raimondi A, Morano F, Mosconi S, Rimassa L, Murgioni S, Sartore-Bianchi A, Tomasello G, Longarini R, Farina G, Petrelli F, Gori S, Randon G, Corallo S, Pagani F, Guarini V, Palermo F, Martinetti A, Macagno M, Barault L, Perrone F, Tamborini E, Milione M, Di Nicolantonio F, Di Maio M, Fucà G, Di Bartolomeo M, de Braud F.

Clin Cancer Res. 2019 Nov 18. doi: 10.1158/1078-0432.CCR-19-3024. [Epub ahead of print]

15.

Targeted agents for second-line treatment of advanced hepatocellular carcinoma.

Personeni N, Pressiani T, Bozzarelli S, Rimassa L.

World J Gastrointest Oncol. 2019 Oct 15;11(10):788-803. doi: 10.4251/wjgo.v11.i10.788. Review.

16.

Cabozantinib for the treatment of hepatocellular carcinoma.

Personeni N, Rimassa L, Pressiani T, Smiroldo V, Santoro A.

Expert Rev Anticancer Ther. 2019 Oct;19(10):847-855. doi: 10.1080/14737140.2019.1674141. Epub 2019 Oct 11.

PMID:
31603008
17.

Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib: A Propensity Score Analysis.

Bettinger D, Pinato DJ, Schultheiss M, Sharma R, Rimassa L, Pressiani T, Burlone ME, Pirisi M, Kudo M, Park JW, Buettner N, Neumann-Haefelin C, Boettler T, Abbasi-Senger N, Alheit H, Baus W, Blanck O, Gerum S, Guckenberger M, Habermehl D, Ostheimer C, Riesterer O, Tamihardja J, Grosu AL, Thimme R, Brunner TB, Gkika E.

Liver Cancer. 2019 Jul;8(4):281-294. doi: 10.1159/000490260. Epub 2018 Jul 12. Erratum in: Liver Cancer. 2019 Jul;8(4):295.

18.

Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy.

Morano F, Corallo S, Lonardi S, Raimondi A, Cremolini C, Rimassa L, Murialdo R, Zaniboni A, Sartore-Bianchi A, Tomasello G, Racca P, Clavarezza M, Adamo V, Perrone F, Gloghini A, Tamborini E, Busico A, Martinetti A, Palermo F, Loupakis F, Milione M, Fucà G, Di Bartolomeo M, de Braud F, Pietrantonio F.

J Clin Oncol. 2019 Nov 20;37(33):3099-3110. doi: 10.1200/JCO.19.01254. Epub 2019 Sep 20.

PMID:
31539295
19.

CK7 and consensus molecular subtypes as major prognosticators in V600EBRAF mutated metastatic colorectal cancer.

Loupakis F, Biason P, Prete AA, Cremolini C, Pietrantonio F, Pella N, Dell'Aquila E, Sperti E, Zichi C, Intini R, Dadduzio V, Schirripa M, Bergamo F, Antoniotti C, Morano F, Cortiula F, De Maglio G, Rimassa L, Smiroldo V, Calvetti L, Aprile G, Salvatore L, Santini D, Munari G, Salmaso R, Guzzardo V, Mescoli C, Lonardi S, Rugge M, Zagonel V, Di Maio M, Fassan M.

Br J Cancer. 2019 Oct;121(7):593-599. doi: 10.1038/s41416-019-0560-0. Epub 2019 Sep 2.

PMID:
31474758
20.

Gastric cancer: Translating novels concepts into clinical practice.

Salati M, Orsi G, Smyth E, Aprile G, Beretta G, De Vita F, Di Bartolomeo M, Fanotto V, Lonardi S, Morano F, Pietrantonio F, Pinto C, Rimassa L, Vasile E, Vivaldi C, Zaniboni A, Ziranu P, Cascinu S.

Cancer Treat Rev. 2019 Sep;79:101889. doi: 10.1016/j.ctrv.2019.101889. Epub 2019 Aug 14. Review. Erratum in: Cancer Treat Rev. 2019 Dec;81:101932.

PMID:
31445415
21.

A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the 'BRAF BeCool' study.

Loupakis F, Intini R, Cremolini C, Orlandi A, Sartore-Bianchi A, Pietrantonio F, Pella N, Spallanzani A, Dell'Aquila E, Scartozzi M, De Luca E, Rimassa L, Formica V, Leone F, Calvetti L, Aprile G, Antonuzzo L, Urbano F, Prenen H, Negri F, Di Donato S, Buonandi P, Tomasello G, Avallone A, Zustovich F, Moretto R, Antoniotti C, Salvatore L, Calegari MA, Siena S, Morano F, Ongaro E, Cascinu S, Santini D, Ziranu P, Schirripa M, Buggin F, Prete AA, Depetris I, Biason P, Lonardi S, Zagonel V, Fassan M, Di Maio M.

Eur J Cancer. 2019 Sep;118:121-130. doi: 10.1016/j.ejca.2019.06.008. Epub 2019 Jul 19.

22.

Hepatotoxicity of immune check point inhibitors: Approach and management.

Lleo A, Rimassa L, Colombo M.

Dig Liver Dis. 2019 Aug;51(8):1074-1078. doi: 10.1016/j.dld.2019.06.017. Epub 2019 Jul 8. Review.

PMID:
31296449
23.

Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.

Pietrantonio F, Morano F, Corallo S, Miceli R, Lonardi S, Raimondi A, Cremolini C, Rimassa L, Bergamo F, Sartore-Bianchi A, Tampellini M, Racca P, Clavarezza M, Berenato R, Caporale M, Antista M, Niger M, Smiroldo V, Murialdo R, Zaniboni A, Adamo V, Tomasello G, Giordano M, Petrelli F, Longarini R, Cinieri S, Falcone A, Zagonel V, Di Bartolomeo M, de Braud F.

JAMA Oncol. 2019 Jul 3. doi: 10.1001/jamaoncol.2019.1467. [Epub ahead of print]

24.

Cabozantinib in patients with hepatocellular carcinoma failing previous treatment with sorafenib.

Personeni N, Pressiani T, Rimassa L.

Future Oncol. 2019 Jul;15(21):2449-2462. doi: 10.2217/fon-2019-0026. Epub 2019 Jun 17. Review.

PMID:
31204849
25.

Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma.

Rimassa L, Danesi R, Pressiani T, Merle P.

Cancer Treat Rev. 2019 Jul;77:20-28. doi: 10.1016/j.ctrv.2019.05.004. Epub 2019 May 15. Review.

26.

Budget impact of bimonthly use of cetuximab in patients diagnosed with metastatic colorectal cancer.

Mennini FS, Marcellusi A, Fabiano G, Rimassa L, Santoro A, Personeni N.

Future Oncol. 2019 Jun;15(18):2107-2112. doi: 10.2217/fon-2018-0904. Epub 2019 Jun 4.

PMID:
31161795
27.

Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial.

Di Bartolomeo M, Niger M, Morano F, Corallo S, Antista M, Tamberi S, Lonardi S, Di Donato S, Berardi R, Scartozzi M, Cardellino GG, Di Costanzo F, Rimassa L, Luporini AG, Longarini R, Zaniboni A, Bertolini A, Tomasello G, Pinotti G, Scagliotti G, Tortora G, Bonetti A, Spallanzani A, Frassineti GL, Tassinari D, Giuliani F, Cinieri S, Maiello E, Verusio C, Bracarda S, Catalano V, Basso M, Ciuffreda L, De Vita F, Parra HS, Fornaro L, Caporale M, de Braud F, Pietrantonio F.

BMC Cancer. 2019 Mar 29;19(1):283. doi: 10.1186/s12885-019-5498-3.

28.

The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine.

Rimassa L, Personeni N, Aghemo A, Lleo A.

J Autoimmun. 2019 Jun;100:17-26. doi: 10.1016/j.jaut.2019.03.007. Epub 2019 Mar 9. Review.

PMID:
30862450
29.

Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition.

Rimassa L, Bozzarelli S, Pietrantonio F, Cordio S, Lonardi S, Toppo L, Zaniboni A, Bordonaro R, Di Bartolomeo M, Tomasello G, Dadduzio V, Tronconi MC, Piombo C, Giordano L, Gloghini A, Di Tommaso L, Santoro A.

Clin Colorectal Cancer. 2019 Jun;18(2):125-132.e2. doi: 10.1016/j.clcc.2019.02.004. Epub 2019 Feb 14.

PMID:
30846365
30.

Combined Low Densities of FoxP3+ and CD3+ Tumor-Infiltrating Lymphocytes Identify Stage II Colorectal Cancer at High Risk of Progression.

Cavalleri T, Bianchi P, Basso G, Celesti G, Grizzi F, Bossi P, Greco L, Pitrone C, Valtorta E, Mauri G, Truini M, Dall'Olio FG, Brandi G, Sartore-Bianchi A, Ricciardiello L, Torri V, Rimassa L, Siena S, Mantovani A, Malesci A, Laghi L; Alleanza contro il Cancro (ACC) Colorectal Cancer Working Group.

Cancer Immunol Res. 2019 May;7(5):751-758. doi: 10.1158/2326-6066.CIR-18-0661. Epub 2019 Feb 25.

PMID:
30804005
31.

Nicotinamide Phosphoribosyltransferase Acts as a Metabolic Gate for Mobilization of Myeloid-Derived Suppressor Cells.

Travelli C, Consonni FM, Sangaletti S, Storto M, Morlacchi S, Grolla AA, Galli U, Tron GC, Portararo P, Rimassa L, Pressiani T, Mazzone M, Trovato R, Ugel S, Bronte V, Tripodo C, Colombo MP, Genazzani AA, Sica A.

Cancer Res. 2019 Apr 15;79(8):1938-1951. doi: 10.1158/0008-5472.CAN-18-1544. Epub 2019 Feb 18.

PMID:
30777853
32.

Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date.

Personeni N, Pressiani T, Rimassa L.

J Hepatocell Carcinoma. 2019 Jan 31;6:31-39. doi: 10.2147/JHC.S168953. eCollection 2019. Review.

33.

Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study.

Fanotto V, Fornaro L, Bordonaro R, Rosati G, Rimassa L, Di Donato S, Santini D, Tomasello G, Leone F, Silvestris N, Stragliotto S, Scartozzi M, Giampieri R, Nichetti F, Antonuzzo L, Cinieri S, Avallone A, Pellegrino A, Melisi D, Vasile E, Gerratana L, Aprile G.

J Geriatr Oncol. 2019 Jul;10(4):591-597. doi: 10.1016/j.jgo.2018.11.009. Epub 2018 Dec 11.

PMID:
30551958
34.

Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma.

Mazzaferro V, El-Rayes BF, Droz Dit Busset M, Cotsoglou C, Harris WP, Damjanov N, Masi G, Rimassa L, Personeni N, Braiteh F, Zagonel V, Papadopoulos KP, Hall T, Wang Y, Schwartz B, Kazakin J, Bhoori S, de Braud F, Shaib WL.

Br J Cancer. 2019 Jan;120(2):165-171. doi: 10.1038/s41416-018-0334-0. Epub 2018 Nov 13.

35.

Alpha-fetoprotein screening in patients with hepatitis C-induced cirrhosis who achieved a sustained virologic response in the direct-acting antiviral agents era.

Spadaccini M, Lleo A, Ceriani R, Covini G, Rimassa L, Torzilli G, Di Tommaso L, Aghemo A.

Hepatobiliary Pancreat Dis Int. 2018 Dec;17(6):570-574. doi: 10.1016/j.hbpd.2018.10.006. Epub 2018 Oct 28. No abstract available.

PMID:
30420319
36.

Drugs in Development for Hepatocellular Carcinoma.

Rimassa L.

Gastroenterol Hepatol (N Y). 2018 Sep;14(9):542-544. No abstract available.

37.

Medical oncologists must get more involved in systemic treatment of hepatocellular carcinoma.

Raoul JL, Faivre S, Frenel JS, Rimassa L.

Ann Oncol. 2019 Jan 1;30(1):6-8. doi: 10.1093/annonc/mdy471. No abstract available.

38.

Estimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life Nomogram.

Pietrantonio F, Barretta F, Fanotto V, Park SH, Morano F, Fucà G, Niger M, Prisciandaro M, Silvestris N, Bergamo F, Fornaro L, Bordonaro R, Rimassa L, Santini D, Tomasello G, Antonuzzo L, Noventa S, Avallone A, Leone F, Faloppi L, Di Donato S, de Braud F, Lee J, De Vita F, Di Bartolomeo M, Miceli R, Aprile G.

Oncology. 2018;95(6):344-352. doi: 10.1159/000491753. Epub 2018 Aug 21.

PMID:
30130791
39.

Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications.

Personeni N, Pressiani T, Santoro A, Rimassa L.

Drugs Context. 2018 Jun 27;7:212533. doi: 10.7573/dic.212533. eCollection 2018. Review.

40.

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.

Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, Cicin I, Merle P, Chen Y, Park JW, Blanc JF, Bolondi L, Klümpen HJ, Chan SL, Zagonel V, Pressiani T, Ryu MH, Venook AP, Hessel C, Borgman-Hagey AE, Schwab G, Kelley RK.

N Engl J Med. 2018 Jul 5;379(1):54-63. doi: 10.1056/NEJMoa1717002.

41.

Shaping the landscape of immune oncology in hepatocellular carcinoma.

Personeni N, Rimassa L.

Lancet Oncol. 2018 Jul;19(7):855-856. doi: 10.1016/S1470-2045(18)30383-8. Epub 2018 Jun 3. No abstract available.

PMID:
29875067
42.

Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational Study.

Baretti M, Rimassa L, Personeni N, Giordano L, Tronconi MC, Pressiani T, Bozzarelli S, Santoro A.

Clin Colorectal Cancer. 2018 Sep;17(3):e489-e498. doi: 10.1016/j.clcc.2018.03.010. Epub 2018 Mar 21.

PMID:
29650416
43.

Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.

Rimassa L, Assenat E, Peck-Radosavljevic M, Pracht M, Zagonel V, Mathurin P, Rota Caremoli E, Porta C, Daniele B, Bolondi L, Mazzaferro V, Harris W, Damjanov N, Pastorelli D, Reig M, Knox J, Negri F, Trojan J, López López C, Personeni N, Decaens T, Dupuy M, Sieghart W, Abbadessa G, Schwartz B, Lamar M, Goldberg T, Shuster D, Santoro A, Bruix J.

Lancet Oncol. 2018 May;19(5):682-693. doi: 10.1016/S1470-2045(18)30146-3. Epub 2018 Apr 3.

PMID:
29625879
44.

Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial.

Reni M, Balzano G, Zanon S, Zerbi A, Rimassa L, Castoldi R, Pinelli D, Mosconi S, Doglioni C, Chiaravalli M, Pircher C, Arcidiacono PG, Torri V, Maggiora P, Ceraulo D, Falconi M, Gianni L.

Lancet Gastroenterol Hepatol. 2018 Jun;3(6):413-423. doi: 10.1016/S2468-1253(18)30081-5. Epub 2018 Apr 4.

PMID:
29625841
45.

FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial.

Sobrero A, Lonardi S, Rosati G, Di Bartolomeo M, Ronzoni M, Pella N, Scartozzi M, Banzi M, Zampino MG, Pasini F, Marchetti P, Cantore M, Zaniboni A, Rimassa L, Ciuffreda L, Ferrari D, Zagonel V, Maiello E, Barni S, Rulli E, Labianca R; TOSCA Investigators.

J Clin Oncol. 2018 May 20;36(15):1478-1485. doi: 10.1200/JCO.2017.76.2187. Epub 2018 Apr 5.

PMID:
29620994
46.

Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study.

Di Bartolomeo M, Niger M, Tirino G, Petrillo A, Berenato R, Laterza MM, Pietrantonio F, Morano F, Antista M, Lonardi S, Fornaro L, Tamberi S, Giommoni E, Zaniboni A, Rimassa L, Tomasello G, Sava T, Spada M, Latiano T, Bittoni A, Bertolini A, Proserpio I, Bencardino KB, Graziano F, Beretta G, Galdy S, Ventriglia J, Scagnoli S, Spallanzani A, Longarini R, De Vita F.

Target Oncol. 2018 Apr;13(2):227-234. doi: 10.1007/s11523-018-0562-5.

PMID:
29582224
47.

Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: Are we aware of the therapeutic impact of intratumor heterogeneity?

Baretti M, Personeni N, Destro A, Santoro A, Rimassa L.

Cancer Biol Ther. 2018 Aug 3;19(8):659-663. doi: 10.1080/15384047.2018.1450117. Epub 2018 Apr 13.

48.

Progression of Colorectal Liver Metastases from the End of Chemotherapy to Resection: A New Contraindication to Surgery?

Vigano L, Darwish SS, Rimassa L, Cimino M, Carnaghi C, Donadon M, Procopio F, Personeni N, Del Fabbro D, Santoro A, Torzilli G.

Ann Surg Oncol. 2018 Jun;25(6):1676-1685. doi: 10.1245/s10434-018-6387-8. Epub 2018 Feb 27.

PMID:
29488188
49.

Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy.

Fanotto V, Uccello M, Pecora I, Rimassa L, Leone F, Rosati G, Santini D, Giampieri R, Di Donato S, Tomasello G, Silvestris N, Pietrantonio F, Battaglin F, Avallone A, Scartozzi M, Lutrino ES, Melisi D, Antonuzzo L, Pellegrino A, Ferrari L, Bordonaro R, Vivaldi C, Gerratana L, Bozzarelli S, Filippi R, Bilancia D, Russano M, Aprile G.

Oncologist. 2018 Feb;23(2):272. doi: 10.1634/theoncologist.2017-0158erratum. No abstract available.

50.

Aggressive and Multidisciplinary Local Approach to Iterative Recurrences of Colorectal Liver Metastases.

Viganò L, Pedicini V, Comito T, Carnaghi C, Costa G, Poretti D, Franzese C, Personeni N, Del Fabbro D, Rimassa L, Scorsetti M, Santoro A, Solbiati L, Torzilli G.

World J Surg. 2018 Aug;42(8):2651-2659. doi: 10.1007/s00268-018-4525-x.

PMID:
29423737

Supplemental Content

Loading ...
Support Center